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OBJECTIVE — Despite experimental data suggesting a protective effect of peroxisome pro-
liferator–activated receptor- agonists with respect to malignancies, results of available epide-
miological studies on the incidence of cancer in rosiglitazone-treated patients are not univocal.
The aim of this meta-analysis of randomized clinical trials is to assess the effect of rosiglitazone
on the incidence of cancer.
RESEARCH DESIGN AND METHODS — Randomized clinical trials of rosiglitazone
withdurationof24weekswereretrievedthroughMedlineandfromtheGlaxoSmithKlineWeb
site, which reports main results of all trials sponsored by GlaxoSmithKline; incident malignan-
cies were retrieved from the summary of serious adverse events. Proportions of outcome mea-
sures across treatment groups were compared by odds ratios (ORs) and 95% CI. Considering
differences in the duration of follow-up among treatment arms in some of the trials, we also
calculated the incidence of cancer in rosiglitazone and control groups.
RESULTS — Eighty trials, enrolling 16,332 and 12,522 patients in the rosiglitazone and
comparator groups, respectively, were retrieved. Rosiglitazone was not associated with a signif-
icant modiﬁcation of the risk of cancer (OR 0.91 [95% CI 0.71–1.16], P  0.44). The incidence
of malignancies was signiﬁcantly lower in rosiglitazone-treated patients than in control groups
(0.23 [0.19–0.26] vs. 0.44 [0.34–0.58] cases/100 patient-years; P  0.05).
CONCLUSIONS — The use of rosiglitazone appears to be safe in terms of incidence of
cancer, whereas its possible protective effect needs to be further investigated.
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T
wo epidemiological surveys pro-
vided discordant results on the ef-
fects of rosiglitazone on the
incidence of malignancies. One study re-
ported a speciﬁc reduction in the inci-
denceoflungcancer(1),whereasanother
survey suggested an increased risk of ma-
lignancies, without providing informa-
tion on types of cancer (2).
A hypothetical anticancer effect of
thiazolidinediones has been suggested on
the basis of their pharmacological proﬁle
of action. The antimitotic and prodiffer-
entiating effects of peroxisome prolifera-
tor–activated receptor (PPAR)- agonists,
whichhavebeendescribedinvitroandin
animal models (3–5), suggested the pos-
sibleuseofthesedrugsasanticancerther-
apy, although the results of preliminary
trials were contradictory (6–10). On the
otherhand,themechanismsunderlyinga
possible mitogenic effect of PPAR- acti-
vatorshavenotbeenidentiﬁedsofar.The
aim of the present meta-analysis is to as-
sesstheriskofcancerassociatedwithros-
iglitazone treatment, compared either
with placebo or active hypoglycemic
drugs.
RESEARCH DESIGN AND
METHODS— Trials were identiﬁed
through a search of a Web site of Glaxo-
SmithKline (GSK) (11), manufacturer of
rosiglitazone,whichcontainsresultsofall
completed trials sponsored by GSK, with
a description of all serious adverse events
(includingthoseconsiderednotrelatedto
study drug), such as incident malignan-
cies. Published trials sponsored by other
companies or by academic institutions
were retrieved through a Medline search
for all randomized controlled trials with
rosiglitazone performed in humans with
results published in English up to 5 Feb-
ruary 2008. For each trial, all fatal and
nonfatal serious adverse events in each
treatment arm are listed with a brief de-
scription. All studies comparing rosiglita-
zone with placebo or other active drugs,
with a duration 24 weeks, were in-
cluded in the analysis. Studies of shorter
duration were excluded, considering that
a brief exposure to a drug is unlikely to
have any impact on the incidence of can-
cer. Occurrences of fatal or nonfatal can-
cer were extracted from serious adverse
events.
After the exclusion of trials with zero
events, odds ratios (ORs) and 95% CI,
with the Mantel-Haenszel (MH)-OR
weighting procedure, were calculated us-
ing a random effect model. This proce-
dure was chosen to overcome the
limitations of the Peto method (12–14),
which had been used in a previous meta-
analysis on cardiovascular effects of ros-
iglitazone (15). In fact, the Peto method
overestimates differences between treat-
mentswhenalargenumberofsmalltrials,
with few events, are included in a meta-
analysis (12–14). Separate analyses were
performed, whenever possible, for trials
with different comparators and for those
performed in type 2 diabetic or nondia-
betic patients, as well as for trials with
duration 52 weeks. Separate analyses
were also performed for the most com-
mon individual types of cancer.
Considering that in the largest trial
included in the analysis (16) the duration
of follow-up in the rosiglitazone arm is
longer than in comparators (17), we also
calculated the actual incidence density of
cancerindifferenttreatmentgroupsusing
a random effect model, assuming that
rates of loss at follow-up, mortality, and
incidence of malignancies were constant
throughout the duration of each trial; this
analysis also included trials with zero
events. Furthermore, after determination
of effect sizes for individual trials, ratios
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lated for each trial and combined to ob-
tain a pooled rate ratio. All of the analyses
were performed using Comprehensive
Meta Analysis (version 2.2.046; Engle-
wood, NJ).
RESULTS— The trial ﬂow is summa-
rized in Fig. 1. The 80 trials included in
the analysis enrolled 16,332 and 12,522
patients for rosiglitazone and compara-
tors (15,700 and 18,050 patient-years),
respectively, with a weighted mean age of
55.3 years. Of the retrieved trials, 63 and
17 were performed on type 2 diabetic pa-
tients (mean A1C 8.1%) or on subjects
with different conditions, respectively
(Table 1). Most (25 of 51) of the pub-
lished trials not present on the GSK Web
site(11)didnotreportadetaileddescrip-
tion of serious adverse events, including
malignancies; only two malignancies had
been observed in those trials for which
this information was available. A com-
plete list of published trials not on GSK
Web site, either included or not included
inthemeta-analysis,isreportedintheon-
line appendix (available at http://
dx.doi.org/10.2337/dc07-2308).
The number of incident malignancies
reported in each trial is summarized in
Table 1. Of the 302 cases of cancer, 42
(13.9%) were gastrointestinal, 13 (4.3%)
pancreatic, 26 (8.6%) pulmonary, 35
(11.6%) of mammary gland/female geni-
tal tract, 36 (11.9%) of male urogenital
tract, and 105 (34.8%) of other known
origin; the type of cancer was not speci-
ﬁed in 45 (14.9%) cases. No difference
was observed in the proportion of cases
between patients allocated to rosiglita-
zone and comparators. The overall
MH-OR [95% CI] for rosiglitazone com-
pared with control groups was 0.91
([0.71–1.16]; P  0.44). More than one-
half of all malignancies were observed in
one large trial, A Diabetes Outcome Pro-
gressionTrial(ADOPT);theMH-ORafter
the exclusion of this study was 0.92
(0.61–1.39). When trials with a duration
52 weeks were analyzed separately, the
MH-ORforrosiglitazonewas0.86(0.66–
1.14). Similar results were obtained for
nondiabetic and type 2 diabetic patients
(0.93 [0.33–2.65] and 0.91 [0.71–1.17],
respectively), for different comparators,
andforthemostcommontypesofcancer,
when analyzed separately (Fig. 2). Sepa-
rate analyses on individual malignancies
in trials with different comparators were
not performed because of the insufﬁcient
numberofeventsrecordedineachgroup.
The cumulative incidence density of
cancer in the rosiglitazone group was sig-
niﬁcantly (P  0.05) lower than that in
comparators (0.23 [95% CI 0.19–0.26]
vs. 0.44 [0.34–0.58] cases/100 patient-
years;P0.05).Thepooledrateratiofor
rosiglitazone (versus comparators) was
1.02 (95% CI 0.67–1.57).
CONCLUSIONS — Available data
from randomized clinical trials, summa-
rized in the present meta-analysis, do not
support the recent hypothesis of an in-
creasedriskofcancerassociatedwithrosi-
glitazone (2). On the contrary, the
incidence of malignancies in patients re-
ceiving rosiglitazone is not higher than
thatobservedwithcomparators,although
a possible protective effect of the drug, as
suggested by previous observations, was
not conﬁrmed by the present data (1). In
consideration of the fact that metformin
treatment is associated with reduced risk
of cancer in epidemiological studies (18),
thehypothesisofaprotectiveeffectattrib-
utabletoenhancementofinsulinsensitiv-
ity and/or reduction of circulating insulin
levels should be considered, along with
other more direct, PPAR-–dependent or
–independenteffectsofthedrug(4,5,19).
However, the pooled rate ratio did not
highlightanyeffectofrosiglitazoneonthe
risk of cancer. This discrepancy could be
due to the fact that the proportion of sub-
jects receiving rosiglitazone and control
treatments varies across trials enrolling
patients with different characteristics,
which may affect the incidence of cancer.
It should also be considered that inci-
dencedensitiesandrateratiosreportedin
the present analysis were obtained on the
basis of several problematic assumptions
(i.e., that rates of loss at follow-up, mor-
tality,andincidenceofmalignancieswere
constant throughout the duration of each
trial); these results should therefore be
considered with caution. A meta-analysis
of rosiglitazone trials based on patient-
level data should be performed to gather
more reliable information on this issue.
The gold standard for the assessment
of the effects of drug treatments on major
outcomes is represented by speciﬁcally
designed and appropriately sized ran-
domized clinical trials. Unfortunately, in
the case of hypoglycemic drugs, such tri-
alsareoftenunavailable.Therefore,meta-
analyses of events occurring in
randomized trials designed with different
end points have been used as a surrogate
source of information (15). The limita-
tions of this procedure should be clearly
recognized; in particular, the classiﬁca-
tion of outcomes reported as adverse
events and not as predeﬁned end points
can be problematic. Notably, most pub-
Figure 1—Flow diagram of the trials evaluated for inclusion in the meta-analysis. SAE, serious
adverse events.
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Study (11)* Characteristics Comparator
Duration
(weeks)
Number
R/C
Mean
age
(years)
Mean
A1C
(%)
Incident
cases of
cancer R/C
Nondiabetic subjects
Trials on GSK Web site
100684 Metabolic
syndrome
Placebo 52 43/47 45 — 0/0
49653/330 Plaque psoriasis Placebo 52 1,181/382 44 — 3/1
49653/331 Plaque psoriasis Placebo 52 706/325 45 — 0/1
49653/334 Insulin resistant Placebo 52 178/177 68 — 4/3
49653/392 Insulin resistant Metformin 52 16/15 56 — 0/0
49653/131 Insulin resistant Placebo 26 39,427 48 — 0/0
49653/452 Multiple sclerosis Placebo 26 26/25 42 — 0/1
ARA102198 Rheumatoid
arthritis
Placebo 26 49/49 56 — 0/0
AVA100193 Alzheimer’s disease Placebo 24 394/124 71 — 0/0
Other published trials
Carr HIV infection Placebo 48 53/55 45 — 1/0
Sidhu Coronary artery
disease
Placebo 48 46/46 62 — 0/0
Silic HIV infection Metformin 48 30/30 42 — 0/0
van Wijk HIV infection Metformin 26 19/20 47 — 0/0
Coll HIV infection Metformin 26 15/16 48 — 0/0
Cavalcanti HIV infection Placebo 24 48/48 47 — 0/0
Baillargeon PCOS Placebo 24 42/30 27 — 0/0
Lemay PCOS None 24 15/13 24 — 0/0
Type 2 diabetic patients
Trials on GSK Web site
49653/048 (ADOPT)† Monotherapy Glyburide 208 1,456/1,441 56 7.3 63/71
49653/048 (ADOPT)† Monotherapy Metformin 208 1,456/1,454 57 7.3 63/67
49653/080 Monotherapy Glyburide 156 104/99 56 9.1 1/3
49653/097 Monotherapy Glyburide 148 122/120 56 8.9 1/4
49653/135 Combined therapy Placebo 104 116/111 68 7.4 4/7
49653/211 NYHA-II,
mono-combined
Placebo 52 110/114 64 NR 2/3
49653/020 Monotherapy Glyburide 52 384/203 60 8.2 3/0
AVM100264 Combined therapy Sulfonylureas 52 294/302 59 8.0 2/1
712753/008 Combined therapy None 48 284/135 55 NR 3/0
49653/137 Combined therapy Glyburide 32 204/185 59 8.4 2/4
BRL49653/185 Mono-combined None 32 563/142 59 7.4 4/2
SB-712753/003 Combined therapy Placebo 32 254/272 59 7.2 0/1
SB-712753/007† Monotherapy, OL Metformin 32 159/154 59 7.2 0/0
SB-712753/007† Combined therapy,
OL
None 32 155/154 59 7.2 0/0
49653/128 Combined therapy Placebo 28 39/38 58 9.6 0/0
49653/134 Combined therapy Placebo 28 561/276 55 8.7 0/2
SB-797620/004 Monotherapy Glimepiride 28 232/225 53 9.0 1/0
49653/024 Monotherapy Placebo 26 774/185 57 8.9 5/1
49653/044 Combined therapy Placebo 26 71/34 54 9.6 0/0
49653/079 Monotherapy Glyburide 26 104/106 58 9.2 1/0
49653/079 Combined therapy Placebo 26 99/106 58 9.2 2/0
49653/082 Combined therapy Placebo 26 212/107 56 9.1 0/0
49653/085 Combined therapy Placebo 26 138/139 61 NR 1/0
49653/093† Monotherapy Metformin 26 107/109 59 8.7 0/0
49653/093† Combined therapy Placebo 26 106/109 59 8.7 0/0
49653/094 Combined therapy Placebo 26 232/116 58 8.8 0/0
49653/095 Combined therapy Placebo 26 196/96 58 9.0 1/0
49653/096 Combined therapy Placebo 26 232/115 60 9.1 2/0
Continued on following page
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on incident malignancies; cases could be
easily identiﬁed only in trials reported on
the GSK Web site (11), which contains a
detailed description of all serious adverse
events. Furthermore, the inclusion in a
meta-analysis of many small trials with a
very low number of events poses chal-
lenging problems in statistical analysis
(12–14).Itshouldalsobeconsideredthat
clinical trials usually enroll relatively
young patients with low comorbidity and
high compliance, who can be considered
to have a low risk for cancer.
On the other hand, a trial assessing
the effect of a hypoglycemic drug on the
incidence of malignancies would be hy-
pothetically very difﬁcult to realize be-
cause of the required sample size and
durationoffollow-up.Forthisreason,in-
formation on this end point can be ob-
tained only through epidemiological
studiesormeta-analysesoftrialsdesigned
for other purposes. The epidemiological
Table 1—Continued
Study (11)* Characteristics Comparator
Duration
(weeks)
Number
R/C
Mean
age
(years)
Mean
A1C
(%)
Incident
cases of
cancer R/C
49653/109 Monotherapy Glipizide 26 52/25 53 8.0 0/0
49653/125 Combined therapy,
OL
None 26 175/173 56 8.9 0/0
49653/127 Combined therapy Placebo 26 56/58 60 9.0 0/2
49653/136 Combined therapy Placebo 26 148/143 65 8.2 2/0
49653/145 Combined therapy None 26 231/242 61 8.6 1/0
49653/147 Combined therapy Placebo 26 89/88 54 9.1 0/0
49653/162 Combined therapy Placebo 26 168/172 60 8.0 2/0
49653/234 Combined therapy Placebo 26 116/61 63 8.1 1/0
49653/390 Combined therapy None 26 33/30 NR NR 1/0
49653/369 Monotherapy Glyburide 26 25/24 52 6.8 0/0
49653/132 Combined therapy Placebo 24 442/112 59 9.8 1/1
49653/347 Combined therapy Placebo 24 418/212 53 9.0 0/1
49653/015 Combined therapy Placebo 24 395/198 61 9.2 4/0
49653/284 Combined therapy Placebo 24 382/384 55 8.0 1/0
SB-712753/002 Combined therapy Placebo 24 288/280 58 7.5 1/0
49653/090 Monotherapy Placebo 24 228/75 59 8.8 1/0
49653/325 Combined therapy Placebo 24 196/195 53 8.0 0/1
SB-712753/009 Combined therapy Placebo 24 162/160 57 8.7 2/0
AVD102209 Combined therapy Placebo 24 132/131 56 9.6 0/0
49653/143 Combined therapy Placebo 24 121/124 52 9.2 1/0
49653/207 Children
monotherapy
Metformin 24 99/101 14 8.0 0/0
49653/282 Combined therapy Glyburide 24 69/72 60 7.6 0/0
Other published trials
Ko Combined therapy Insulin 52 56/56 58 9.6 0/0
Derosa (a) Combined therapy Glimepiride 52 49/50 53 8.0 0/0
Derosa (b) Combined therapy Pioglitazone 52 48/48 55 9.0 0/0
Derosa (c) Monotherapy Pioglitazone 52 45/42 54 8.1 0/0
Rahman Monotherapy Placebo 52 11/11 47 7.5 0/0
Kelly Combined therapy Glyburide 26 20/16 60 7.6 0/0
Reynolds Monotherapy Placebo 26 8/10 49 9.2 0/0
Osman Monotherapy,
PTCA
Placebo 26 8/8 55 9.6 0/0
Zhou Combined therapy Placebo 24 442/112 56 9.8 0/0
Goldberg Monotherapy Pioglitazone 24 369/366 56 7.5 0/0
Weissman Combined therapy Placebo 24 358/351 55 8.0 0/0
Agrawal Combined therapy None 24 288/280 58 7.5 0/0
Dailey Combined therapy Placebo 24 181/184 57 8.1 0/1
Garber Combined therapy Glyburide 24 158/160 56 8.5 0/0
Wang Mono-combined None 24 35/35 61 7.3 0/0
Wong Combined therapy None 24 26/26 62 7.2 0/0
Jung Combined therapy Metformin 24 15/15 57 9.1 0/0
Total — — 39.2 16,332/12,522 55.3 8.1 124/178
*See APPENDIX for references. †Trials with multiple comparators. ADOPT, A Diabetes Outcome Progression Trial; mono-combined, monotherapy or combined
therapy; NR, not reported; NYHA-II, New York Heart Association, Class II; OL, open label; PCOS, polycystic ovary syndrome; PTCA, percutaneous transluminal
coronary angioplasty; R/C, rosiglitazone versus comparator.
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possibility of collecting large samples
with a long duration of follow-up; how-
ever,inobservationalstudiesmultiplead-
justmentsforconfounderscanneverfully
eliminate the prescription bias (i.e., the
effect of differences in characteristics of
patientsondifferenttherapeuticchoices).
Such a bias could be responsible for the
discrepancy between our results and
those of a recent cross-sectional survey
(2).
The number of events included in the
present meta-analysis does not allow a re-
liable analysis on speciﬁc types of cancer.
However, our data are consistent with the
possibility of speciﬁc protection from
lungcancer,whichhasbeenreportedpre-
viously in a epidemiological study (1).
Considering that the pathogenesis of dif-
ferent forms of cancer is very heteroge-
neous, the drug could have divergent
effectsondifferentmalignancies.Interest-
ingly, no reduction of risk for cancer of
the female genital tract was detected in
rosiglitazone-treated patients, although
the drug is used in the treatment of poly-
cystic ovary syndrome (20), which is a
known risk factor for these malignancies
(21). Larger databases are needed to elu-
cidatetheriskproﬁleforindividualforms
ofcancerinrosiglitazone-treatedpatients.
In summary, the use of rosiglitazone
appears to be safe with respect to risk of
incident malignancies, whereas further
studies are needed to conﬁrm a possible
protective effect. The incidence of cancer,
whichcanprobablybemodiﬁedbyhypo-
glycemicdrugs,deservestobeconsidered
among the relevant outcomes for the
choice of treatment for type 2 diabetes.
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